September 2009 Volume 9 Number 9
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=93&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Cancer online. To purchase a subscription,
please visit: http://links.ealert.nature.com/ctt?kn=30&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=73&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cancer Impact Factor: 30.762*
* 2008 Journal Citation Report (Thomson Reuters, 2009)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Antibodies For Cancer Research
Buy 1 Get 3 Free!
http://links.ealert.nature.com/ctt?kn=41&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Use Rockland Immunochemicals antibodies and tools
for cancer research to identify candidate biomarkers,
characterize signaling pathways, and measure changes
in modifications or expression levels of cancer-related proteins.
http://links.ealert.nature.com/ctt?kn=22&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Don't see what you need? Contact us about custom monoclonal
antibody production.
http://links.ealert.nature.com/ctt?kn=25&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com
http://links.ealert.nature.com/ctt?kn=59&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
It's the breakthrough you've been waiting for. Naturejobs.com - the
scientific jobs board from Nature now lets you advertise your vacancy
completely FREE OF CHARGE
Go to http://links.ealert.nature.com/ctt?kn=77&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0 or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=========================== ADVERTISEMENT ===========================
AACR Conference:
Advances in Breast Cancer Research: Genetics, Biology and Clinical Applications
October 13-16, 2009 - San Diego, CA
Carlos L. Arteaga, Lewis A. Chodosh, and Kornelia Polyak, Chairpersons
Presenting discoveries in genetics, cell biology, and molecular biology
relevant to breast cancer development and progression. Please visit:
http://links.ealert.nature.com/ctt?kn=45&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0.
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Infectious disease: Rapamycin's immunostimulatory potential
Despite Rapamune's current use as an immunosuppressant, Emory University
researchers think it has promise as an immunostimulatory vaccine adjuvant.
Find out more by reading the first in-depth analysis of the scientific and
commercial potential of the work in SciBX: Science-Business eXchange.
FULL TEXT: http://links.ealert.nature.com/ctt?kn=24&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=72&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
ACCESS 30 FREE ARTICLES from the SciBX Cover Story Archive HERE
http://links.ealert.nature.com/ctt?kn=18&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=====================================================================
This month's Featured article:
Normal and cancer-related functions of the p160 steroid receptor co-activator
(SRC) family
Jianming Xu, Ray-Chang Wu and Bert W. O'Malley
p615 | doi:10.1038/nrc2695
http://links.ealert.nature.com/ctt?kn=11&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=====================================================================
From the editors
p607 | doi:10.1038/nrc2729
http://links.ealert.nature.com/ctt?kn=44&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Metastasis: Influencing bad behaviour
p609 | doi:10.1038/nrc2720
http://links.ealert.nature.com/ctt?kn=49&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Tumour suppressors: Different roads to inactivation
p610 | doi:10.1038/nrc2719
http://links.ealert.nature.com/ctt?kn=51&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Metastasis: Route master
p610 | doi:10.1038/nrc2721
http://links.ealert.nature.com/ctt?kn=53&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
IN BRIEF
Apoptosis | Prostate cancer
p611 | doi:10.1038/nrc2727
http://links.ealert.nature.com/ctt?kn=39&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Small RNAs: p53 makes microRNAs mature
p612 | doi:10.1038/nrc2724
http://links.ealert.nature.com/ctt?kn=2&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Tumour suppression: Full on
p612 | doi:10.1038/nrc2725
http://links.ealert.nature.com/ctt?kn=5&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
IN BRIEF
Breast cancer | Oncogenes | Metabolism | Hypoxia
p612 | doi:10.1038/nrc2726
http://links.ealert.nature.com/ctt?kn=36&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Tumorigenesis: Replicating recurrence
p613 | doi:10.1038/nrc2722
http://links.ealert.nature.com/ctt?kn=81&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
AACR Conference:
Advances in Breast Cancer Research: Genetics, Biology and Clinical App
lications
October 13-16, 2009 - San Diego, CA
Carlos L. Arteaga, Lewis A. Chodosh, and Kornelia Polyak, Chairpersons
Presenting discoveries in genetics, cell biology, and molecular biolog
y relevant to breast cancer development and progression. Please visit
http://links.ealert.nature.com/ctt?kn=45&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0.
=====================================================================
----------------------
REVIEWS
----------------------
Normal and cancer-related functions of the p160 steroid receptor co-activator
(SRC) family
Jianming Xu, Ray-Chang Wu and Bert W. O'Malley
p615 | doi:10.1038/nrc2695
Recent work has indicated that the p160 SRC family of transcriptional
co-activators are subject to amplification and overexpression in various
human cancers. This Review discusses the molecular mechanisms responsible,
along with the mechanisms by which SRCs promote breast and prostate cancer
cell proliferation and survival.
Abstract: http://links.ealert.nature.com/ctt?kn=11&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=83&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article series: Therapeutic resistance
http://links.ealert.nature.com/ctt?kn=23&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove and Robert L. Sutherland
p631 | doi:10.1038/nrc2713
The efficacy of endocrine therapies (such as tamoxifen) in breast cancer
is limited by intrinsic and acquired therapeutic resistance. What do we
know about the genetic lesions and molecular processes that determine
endocrine resistance in the clinic, and how can we use this to improve
therapy?
Abstract: http://links.ealert.nature.com/ctt?kn=37&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=66&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
RecQ helicases: multifunctional genome caretakers
Wai Kit Chu and Ian D. Hickson
p644 | doi:10.1038/nrc2682
In recent years, there has been a tremendous advance in our understanding
of the cellular functions of individual RecQ helicases. This Review discusses
how these proteins might suppress genomic rearrangements, and therefore
function as 'caretaker' tumour suppressors.
Abstract: http://links.ealert.nature.com/ctt?kn=31&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=58&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
----------------------
ANALYSIS
----------------------
Avoidable global cancer deaths and total deaths from smoking
Prabhat Jha
p655 | doi:10.1038/nrc2703
Death due to smoking - from cancer, vascular disease or tuberculosis -
is growing worldwide, particularly in low- and middle-income countries,
in which the prevalence of smoking is increasing. How many people could die
from smoking before 2050 and how might this be avoided?
Abstract: http://links.ealert.nature.com/ctt?kn=34&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=62&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
Article series: Therapeutic resistance
http://links.ealert.nature.com/ctt?kn=23&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Opinion
Environment-mediated drug resistance: a major contributor to minimal
residual disease
Mark B. Meads, Robert A. Gatenby and William S. Dalton
p665 | doi:10.1038/nrc2714
How does therapeutic resistance affect disease relapse? Here the authors
argue that the tumour microenvironment mediates a complex form of de novo
drug resistance and that adjuvant inhibition of key stromal factors could
prevent the emergence of therapeutic resistance and relapse.
Abstract: http://links.ealert.nature.com/ctt?kn=28&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=65&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
OPINION
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures
Maurizio Bendandi
p675 | doi:10.1038/nrc2717
The failure of three Phase III randomized trials that assessed the efficacy
of anti-idiotype vaccines for the treatment of follicular lymphoma has raised
many questions and controversies. In this article, Maurizio Bendandi expresses
his thoughts on these findings and argues that new trials are necessary.
Abstract: http://links.ealert.nature.com/ctt?kn=29&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=43&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
New Initiatives at The EMBO Journal
Starting with manuscripts submitted in 2009, The EMBO Journal now publishes
referee reports and author responses for all accepted manuscripts online.
This Transparent Editorial Process initiative also includes statistics on
manuscript handling and follow-up analysis on rejected manuscripts.
In order to encourage citation of relevant primary literature, The EMBO Journal
is also now allowing unlimited references.
Please see our redesigned website for further information
http://links.ealert.nature.com/ctt?kn=27&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=71&m=33902276&r=MTc2Njc4NzkyNgS2&b=2&j=NTcwNjAzMjMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
